artículo académico

• Antivenom against Vipera berus is effective against Macrovipera lebetina.  Toxicon.  159:S32. 2019
• Effect of premedication with subcutaneous adrenaline on the pharmacokinetics and immunogenicity of equine whole IgG antivenom in a rabbit model.  Toxicon.  159:S17-S18. 2019
• Vipera berus berus Venom from Russia: Venomics, Bioactivities and Preclinical Assessment of Microgen Antivenom.  Toxins.  11:90. 2019
• A Synthetic Biology approach for consistent production of plant‐made recombinant polyclonal antibodies against snake venom toxins.  Plant Biotechnology Journal.  16:727-736. 2018
• Aportes del modelo de Yrjö Engeström al desarrollo teórico de la docencia universitaria.  Journal of Proteomics.  181:104-117. 2018
• Current technology for the industrial manufacture of snake antivenoms.  Toxicon.  151:63-73. 2018
• Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom.  Toxicon.  10:380-781. 2018
• Isolation and partial characterization of the insulin-like androgenic gland hormone gene from distal terminal ampoules of the three marine shrimp Litopenaeus species from the Eastern Pacific.  Latin American Journal of Aquatic Research.  46:461-468. 2018
• Robust PI/PID controllers for load disturbance based on direct synthesis.  ISA Transactions.  59:158-162. 2018
• Active immunization of cattle with a bothropic toxoid does not abrogate envenomation by Bothrops asper venom, but increases the likelihood of survival.  Biologicals.  46:1-5. 2017
• An improved technique for the assessment of venom-induced haemorrhage in a murine model.  Toxicon.  139:87-93. 2017
• Comparison of the adjuvant activity of emulsions with different physicochemical properties on the antibody response towards the venom of West African carpet viper (Echis ocellatus).  Toxicon.  127:106-111. 2017
• Cross-reactivity and cross-immunomodulation between venoms of the snakes Bothrops asper , Crotalus simus and Lachesis stenophrys , and its effect in the production of polyspecific antivenom for Central America.  Toxicon.  138:43-48. 2017
• Effect of premedication with subcutaneous adrenaline on the pharmacokinetics and immunogenicity of equine whole IgG antivenom in a rabbit model.  Biomedicine & Pharmacotherapy.  90:740-743. 2017
• Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.  Journal of Proteomics.  150:201-215. 2017
• Expanding the neutralization scope of the EchiTAb-plus-ICP antivenom to include venoms of elapids from Southern Africa.  Toxicon.  125:59-64. 2017
• Freeze-dried EchiTAb+ICP antivenom formulated with sucrose is more resistant to thermal stress than the liquid formulation stabilized with sorbitol.  Toxicon.  133:123-126. 2017
• Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: The GISTAR study.  BMJ Journal.  7:1-7. 2017
• Preclinical Evaluation of the Efficacy of Antivenoms for Snakebite Envenoming: State-of-the-Art and Challenges Ahead.  Toxins.  9:163. 2017
• Proteomic, toxicological and immunogenic characterization of Mexican west-coast rattlesnake (Crotalus basiliscus) venom and its immunological relatedness with the venom of Central American rattlesnake (Crotalus simus).  Journal of Proteomics.  158:62-72. 2017
• Bothrops asper envenoming in cattle: Clinical features and management using equine-derived whole IgG antivenom.  Revista de Biologia Marina y Oceanografia.  207:160-163. 2016
• Development of a chicken-derived antivenom against the taipan snake (Oxyuranus scutellatus) venom and comparison with an equine antivenom.  Toxicon.  120:1-8. 2016
• Development of a new polyspecific antivenom for snakebite envenoming in Sri Lanka: Analysis of its preclinical efficacy as compared to a currently available antivenom.  Toxicon.  122:152-159. 2016
• Journal of Clinical Immunology.  Revista de Biología Tropical.  65. 2016
• Journal of Herpetology.  Toxicon.  119:171-179. 2016
• Neutralization of the neuromuscular inhibition of venom and taipoxin from the taipan (Oxyuranus scutellatus) by F(ab')2 and whole IgG antivenoms.  Toxicology Letters.  241:175-183. 2016
• Effect of geographical variation of Echis ocellatus, Naja nigricollis and Bitis arietans venoms on their neutralization by homologous and heterologous antivenoms.  Toxicon.  108:80-83. 2015
• Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity.  Vox Sanguinis.  108:169-177. 2015
• Lachesis stenophrys venom reduces the equine antibody response towards Bothrops asper venom used as co-immunogen in the production of polyspecific snake antivenom.  Toxicon.  103:99-105. 2015
• Purification of equine whole IgG snake antivenom by using an aqueous two phase system as a primary purification step.  Biologicals.  43:37-46. 2015
• Antivenomic characterization of two antivenoms against the venom of the taipan, Oxyuranus scutellatus, from Papua New Guinea and Australia.  American Journal of Tropical Medicine and Hygiene.  91:887-894. 2014
• Industrial Production and Quality Control of Snake Antivenoms.  Toxinology.  24:1-22. 2014
• Toxicity of Bothrops sp snake venoms from Ecuador and preclinical assessment of the neutralizing efficacy of a polyspecific antivenom from Costa Rica.  Toxicon.  88:34-37. 2014
• Assessing the preclinical efficacy of antivenoms: From the lethality neutralization assay to antivenomics.  Toxicon.  69:168-179. 2013
• Assessment of snake antivenom purity by comparing physicochemical and immunochemical methods.  Biologicals.  41:93-97. 2013
• Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms.  Toxicon.  76:63-76. 2013
• Role of the animal model on the pharmacokinetics of equine-derived antivenoms.  Toxicon.  70:9-14. 2013
• 210. Understanding the Preclinical Efficacy Profile of Antivenoms: From the Lethality Potency Assay to Antivenomics.  Toxicon.  60:203. 2012
• Comparative proteomic analysis of the venom of the taipan snake, Oxyuranus scutellatus, from Papua New Guinea and Australia: Role of neurotoxic and procoagulant effects in venom toxicity.  Journal of Proteomics.  75:2128-2140. 2012
• Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia.  Toxicon.  59:344-355. 2012
• Low pH formulation of whole IgG antivenom: Impact on quality, safety, neutralizing potency and viral inactivation.  Biologicals.  40:129-133. 2012
• Purification of IgG and albumin from human plasma by aqueous two phase system fractionation.  Biotechnology Progress.  28:1005-1011. 2012
• Snake venomics and antivenomics of Protobothrops mucrosquamatus and Viridovipera stejnegeri from Taiwan: Keys to understand the variable immune response in horses.  Journal of Proteomics.  75:5628-5645. 2012
• Atherosclerosis.  Journal of Proteome Research.  10:1266-1280. 2011
• Comparison of the effect of Crotalus simus and Crotalus durissus ruruima venoms on the equine antibody response towards Bothrops asper venom: Implications for the production of polyspecific snake antivenoms.  Toxicon.  57:237-243. 2011
• Immune response towards snake venoms.  Inflammation and Allergy - Drug Targets.  10:381-398. 2011
• Preclinical evaluation of caprylic acid-fractionated igg antivenom for the treatment of taipan (Oxyuranus scutellatus) envenoming in Papua New Guinea.  PLoS Neglected Tropical Diseases.  5. 2011
• Consultorías en ciencias de la salud.  Toxicon.  55:642-645. 2010
• Intravenous administration of equine-derived whole IgG antivenom does not induce early adverse reactions in non-envenomed horses and cows.  Biologicals.  38:664-669. 2010
• Preclinical assessment of the efficacy of a new antivenom (EchiTAb-Plus-ICP (R)) for the treatment of viper envenoming in sub-Saharan Africa.  Toxicon.  55:369-374. 2010
• Preclinical assessment of the neutralizing capacity of antivenoms produced in six Latin American countries against medically-relevant Bothrops snake venoms.  Toxicon.  56:980-989. 2010
• Study of the design and analytical properties of the lethality neutralization assay used to estimate antivenom potency against Bothrops asper snake venom.  Biologicals.  38:577-585. 2010
• Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom.  Biologicals.  37:306-312. 2009
• Snake venomics and antivenomics of Bothrops colombiensis, a medically important pitviper of the Bothrops atrox-asper complex endemic to Venezuela: Contributing to its taxonomy and snakebite management.  Journal of Proteomics.  72:227-240. 2009
• Stability of equine IgG antivenoms obtained by caprylic acid precipitation: towards a liquid formulation stable at tropical room temperature.  Toxicon.  53:609-615. 2009
• Human heterophilic antibodies against equine immunoglobulins: assessment of their role in the early adverse reactions to antivenom administration.  Transactions of the Royal Society of Tropical Medicine and Hygiene.  102:1115-1119. 2008